GO2 For Lung Cancer

A lung cancer diagnosis can bring a flood of new information and unfamiliar terms. Questions about treatment, side effects, biomarkers, clinical trials, and caregiving can quickly feel overwhelming.

A lung cancer diagnosis can feel overwhelming, but no one should have to navigate it alone. Connecting with others who understand what you're experiencing can provide comfort, practical advice, and hope when you need it most.

GO2 for Lung Cancer (GO2) is proud to announce Jennifer W. Li, MD, of Johns Hopkins University, as the recipient of the 2026 Conquer Cancer – GO2 for Lung Cancer Young Investigator Award in memory of Debbie Consiglio.

Small cell lung cancer (SCLC) can feel overwhelming. Because it is less common and tends to grow and spread quickly, people diagnosed with SCLC often face unique challenges and urgent decisions. Patients and caregivers may find themselves searching for trusted information, support, and guidance as they navigate an unfamiliar path.

When you’re facing lung cancer, the questions can feel endless. What tests should I have? What are my treatment options? Where do I begin? GO2 for Lung Cancer’s HelpLine is often the first step toward clarity and support.

The absence of tobacco use suggests alternative carcinogenic mechanisms may contribute to lung cancer development in younger individuals.

GO2's Lung Cancer Voices Summit is where our community rises together

Lung Cancer Voices Summit Calls on Congress: Support Research. Save Lives.

A nurse practitioner explains how FDA approval of subcutaneous Rybrevant may reduce treatment burden and improve care for patients with EGFR-mutated lung cancer.

A groundbreaking new open-access textbook, “Lung Cancer Navigation and Care: A Comprehensive Guide for Navigators and Allied Health Professionals,” is now available. As the first site-specific, comprehensive clinical guide for lung cancer navigation, the textbook equips navigators and allied health professionals with foundational knowledge, evidence-based practices, and practical tools to elevate the quality of lung cancer care and improve outcomes for people at risk for or living with the disease.

Innovative decentralized trial aims to increase patient participation and accelerate research for one of the deadliest, under-researched lung cancers

As the nation recognizes May as Women’s Health Month, GO2 for Lung Cancer (GO2) is proud to celebrate a milestone: the Women and Lung Cancer Research and Preventive Services Act of 2025 (H.R. 2319) has successfully advanced through the House Energy and Commerce Committee and is now heading to the Senate.

GO2 for Lung Cancer (GO2) announced it established the Global Advisory Council (GAC), a new group that brings together scientists, medical specialists, and other healthcare professionals from diverse disciplines who focus on GO2’s areas of impact: healthcare delivery, patient education, policy, and research. The GAC provides recommendations to guide GO2’s program and project development.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

GO2 for Lung Cancer launched a new awareness campaign to educate the public on the importance of screening for those at risk for lung cancer. The PSA, titled “Screens,” features acclaimed actor and director Tony Goldwyn. As someone who attends many screenings, Goldwyn emphasizes how a lung cancer screening is important, different, and lifesaving.

GO2 for Lung Cancer (GO2) recognized lung cancer champions at its 19th Annual Simply the Best Gala in San Francisco on Nov. 2. This event celebrated organizations and individuals across the lung cancer community, including industry partners, survivors, caregivers, and donors.

GO2 for Lung Cancer presented Pasi A. Jӓnne, M.D, Ph.D. with the 2024 Bonnie J. Addario Lectureship Award for his commitment and dedication to research and development of therapeutic strategies for patients with epidermal growth factor receptor (EGFR) mutant lung cancer.

On Tuesday, March 5th GO2 for Lung Cancer (GO2) hosted more than 200 supporters on Capitol Hill to educate members of Congress on the urgent needs of the lung cancer community.

In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), GO2’s medical research consortium, announced a major expansion of landmark research studying genetic risk for developing lung cancer.

GO2 for Lung Cancer President and CEO Laurie Ambrose submitted testimony to the House Committee on Energy and Commerce, Subcommittee on Health.

There are two different types of lung cancer — small cell and non-small cell lung cancer — that behave differently and therefore require different treatments, an expert explained.

GO2 for Lung Cancer (GO2) applauded the efforts of a bipartisan and bicameral group of lawmakers to address the public health imperative affecting women impacted by lung cancer – the leading cause of cancer death among women.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

Aimee shares how "GO2 very positively impacted" her father's lung cancer journey.

Donna was diagnosed with stage 4 lung cancer right after the birth of her second child. She turned to GO2 for help and support during this very difficult time.

Doubling the funding for research focused on women and lung cancer will have enormous economic impacts for families and the nation, according to a new report released today by Women’s Health Access Matters (WHAM), which commissioned The RAND Corporation to create this study on lung cancer in women.

A groundbreaking new survey, conducted by a multi-disciplinary team in GO2 for Lung Cancer’s Lung Cancer Registry, found that sexual dysfunction is prevalent in women with lung cancer.